{"filing":{"accession_number":"0001193125-26-271793","cik":"0001778016","ticker":"NBP","company_name":"NovaBridge Biosciences","form":"6-K","filing_date":"2026-06-16","report_date":null,"primary_document":"6-k_-_fda_ftd.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1778016/000119312526271793/6-k_-_fda_ftd.htm"},"events":[{"id":12326,"run_id":10894,"accession_number":"0001193125-26-271793","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"NovaBridge announced FDA Fast Track Designation for givastomig in first-line HER2-negative metastatic gastric cancer, a significant regulatory milestone that accelerates development and review. While not a discrete M\u0026A, financing, or executive event, this regulatory achievement materially advances the company's clinical development pathway and would affect a reasonable investor's assessment of the drug candidate's prospects. The designation enables more efficient progress toward a registrational Phase 3 trial and potential accelerated approval, representing a material operational and strategic advancement.","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-06-16","form":"6-K","submitted_at":null,"items":[{"id":9149,"accession_number":"0001193125-26-271793","item_number":"EX-99.1","item_title":"nbp-ex99_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"NovaBridge announced FDA Fast Track Designation for givastomig in first-line HER2-negative metastatic gastric cancer, a significant regulatory milestone that accelerates development and review. While not a discrete M\u0026A, financing, or executive event, this regulatory achievement materially advances the company's clinical development pathway and would affect a reasonable investor's assessment of the drug candidate's prospects. The designation enables more efficient progress toward a registrational Phase 3 trial and potential accelerated approval, representing a material operational and strategic advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:38:02.995831+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9149,"accession_number":"0001193125-26-271793","item_number":"EX-99.1","item_title":"nbp-ex99_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"NovaBridge announced FDA Fast Track Designation for givastomig in first-line HER2-negative metastatic gastric cancer, a significant regulatory milestone that accelerates development and review. While not a discrete M\u0026A, financing, or executive event, this regulatory achievement materially advances the company's clinical development pathway and would affect a reasonable investor's assessment of the drug candidate's prospects. The designation enables more efficient progress toward a registrational Phase 3 trial and potential accelerated approval, representing a material operational and strategic advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:38:02.995831+00:00","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-06-16"}]}